Resistance to Antiestrogen Arzoxifene Is Mediated by Overexpression of Cyclin D1

AUTOR(ES)

Zwart, Wilbert

FONTE

The Endocrine Society

RESUMO

Resistance to tamoxifen treatment occurs in approximately 50% of the estrogen receptor (ER)α-positive breast cancer patients. Resistant patients would benefit from treatment with other available antiestrogens. Arzoxifene is an effective growth inhibitor of ERα-positive breast cancer cells, including tamoxifen-resistant tumors. In this study, we show that overexpression of a regular component of the ERα transcription factor complex, cyclin D1, which occurs in approximately 40% of breast cancer patients, renders cells resistant to the new promising antiestrogen, arzoxifene. Overexpression of cyclin D1 alters the conformation of ERα in the presence of arzoxifene. In this altered conformation, ERα still recruits RNA polymerase II to an estrogen response element-containing promoter, inducing transcription of an ERα-dependent reporter gene and of endogenous pS2, and promoting arzoxifene-stimulated growth of MCF-7 cells. Arzoxifene is then converted from an ERα antagonist into an agonist. This can be explained by a stabilization of the ERα/steroid receptor coactivator-1 complex in the presence of arzoxifene, only when cyclin D1 is overexpressed. These results indicate that subtle changes in the conformation of ERα upon binding to antiestrogen are at the basis of resistance to antiestrogens.

Documentos Relacionados

• Down-Regulation of Cyclin D1 Expression by Prostaglandin A2 Is Mediated by Enhanced Cyclin D1 mRNA Turnover
• Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice
• Cyclin D1 expression is regulated by the retinoblastoma protein.
• Inhibition of Cyclin D1 Kinase Activity Is Associated with E2F-Mediated Inhibition of Cyclin D1 Promoter Activity through E2F and Sp1
• Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice.